CROS NT Acquires PM Clinical Division
Maidenhead, UK and Chapel Hill, NC – CROS NT today announced the acquisition of the clinical division of PM Clinical Limited, a sister company under the PM Holding entity currently based in the United Kingdom and Italy.
The move expands CROS NT’s service offerings by adding regulatory consultancy, study design, feasibility, clinical project management and monitoring. The acquisition shifts CROS NT from a biometrics-only CRO to a niche provider of data expertise combined with clinical excellence to now offer a full service approach.
Andrew MacGarvey, CEO of CROS NT said, “this was a strategic business decision to combine its long standing expertise in clinical data services with PM Clinical’s extensive experience in clinical operations to offer our growing, global customer base a full range of services. Our clients can now rely on one provider, with expertise, flexibility and attention to detail and quality, for full product or device development.”
About CROS NT
Founded in 1992, CROS NT is a data-driven Contract Research Organization (CRO) providing services from feasibility to clinical study reporting for Phases I-IV and medical device trials. CROS NT’s services include regulatory consultancy, monitoring, data management, biostatistics programming & analysis, pharmacovigilance and medical writing – and accompanying eClinical applications (data visualization, EDC, IWRS, eCOA/ePRO etc.). All services are underpinned by strong clinical and biometrics project management with offices located in Europe, the USA and India.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
